Evidence map›Paper›PMID 31102094›Full record

ArticleAnnals of surgical oncology2019

Primary Gallbladder Neuroendocrine Tumors: Insights into a Rare Histology Using a Large National Database.

Reed I Ayabe, Michael Wach, Samantha Ruff, Sean Martin, Laurence Diggs, Timothy Wiemken, Leslie Hinyard, Jeremy L Davis, Carrie Luu, Jonathan M Hernandez

Open access · greenAbstract read
In one paragraph

Article in Annals of surgical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Large Cell Neuroendocrine Carcinoma of Gallbladder: A Case Report.JNMA; journal of the Nepal Medical Association · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Reed I AyabeSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Michael WachSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Samantha RuffSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Sean MartinSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Laurence DiggsDivision of General Surgery, Department of Surgery, Saint Louis University Hospital, St. Louis, MO, USA.
Timothy WiemkenSaint Louis University Center for Health Outcomes Research (SLUCOR), St. Louis, MO, USA.
Leslie HinyardSaint Louis University Center for Health Outcomes Research (SLUCOR), St. Louis, MO, USA.
Jeremy L DavisSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Carrie LuuDivision of General Surgery, Department of Surgery, Saint Louis University Hospital, St. Louis, MO, USA.
Jonathan M HernandezSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. jonathan.hernandez@nih.gov.
National Institutes of Health · USNational Cancer Institute · USSaint Louis University · USSaint Louis University Hospital · US

Funding

Interrogating the molecular underpinnings of metastatic colonizationZIABC011759 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HERNANDEZ, JONATHAN · 2017 to 2025
$18.9M
Evaluating outcomes for patients with primary-metastatic gastrointestinal cancerZIABC011861 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HERNANDEZ, JONATHAN · 2019 to 2025
$166k
Intramural NIH HHS ZIA BC011759
6 · The paper itself

Abstract

backgroundPrimary gallbladder neuroendocrine tumors (NETs) are rare, poorly understood cancers infrequently encountered at even the largest of tertiary referral centers. We therefore sought to identify a large cohort of patients with gallbladder NETs using a national database, with the aim of defining treatment modalities employed and survival associated with these uncommon malignancies.

methodsPatients with primary gallbladder NETs were identified in the National Cancer Database, and clinicopathologic characteristics were recorded. A univariate log-rank survival analysis was completed for patients who underwent resection. Parameters found to be significant were entered into a multivariate accelerated failure time analysis. For context, survival comparisons were included for patients who underwent resections for NETs at any gastrointestinal site and for gallbladder adenocarcinoma.

resultsOverall, 754 patients with gallbladder NETs were identified. Patients were predominantly female (n = 518, 69%), White (n = 503, 67%), presented with stage IV disease (n = 295, 39%) and had high-grade lesions (n = 312, 41%). The majority underwent resection (n = 480, 64%), primarily simple cholecystectomy (n = 431, 90%), whereas a minority received multimodal therapy (n = 145, 21%). Among patients who underwent resection, older age (p = 0.001), large cell histology (p = 0.012), and positive margins (p = 0.030) were independently associated with worse overall survival. Patients with gallbladder NETs had improved survival relative to those with gallbladder adenocarcinoma (p = 0.001), but significantly worse survival than patients with NETs from other gastrointestinal sites (p < 0.001).

conclusionsPrimary gallbladder NETs are aggressive lesions that carry a worse prognosis than NETs of other gastrointestinal sites. Older age, positive margins, and large cell histology are associated with abbreviated survival after resection.

Indexed as

Databases, FactualAdenocarcinomaAgedFemaleFollow-Up StudiesGallbladder NeoplasmsGastrointestinal NeoplasmsHumansMaleNeoplasm MetastasisNeuroendocrine TumorsPrognosisRetrospective StudiesSurvival Rate

Identifiers

PMID31102094
PMCPMC8189165
OpenAlexW2945531157

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.